![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NexMed Completes Enrollment for Study of Topical Antifungal Treatment
NexMed Completes Enrollment for Study of Topical Antifungal Treatment
NexMed has completed enrollment for its Phase I study of NM100060, NexMed's proprietary nail lacquer treatment for onychomycosis (nail fungal infection).
The U.S. Phase I study enrolled a total of 60 patients. The study is double-blind, randomized, parallel designed to assess the safety and pharmacokinetics of NM100060. In the study, the nail lacquer is applied twice a day for 28 days by patients with onychomycosis.
NexMed's lacquer product incorporates NexACT, and is applied directly to the nail and delivers a low dose of terbinafine HCl into the nail bed. Terbinafine is the active ingredient in the leading oral product marketed for treating onychomycosis.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct